Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan · Delayed Price · Currency is TWD 15.85
+0.25 (1.60%)
Jul 30, 2026, 12:38 PM CST
Anxo Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 872 | 1,048 | 1,336 | 2,708 | 1,426 | 1,185 | |
Market Cap Growth | -21.21% | -21.58% | -50.67% | 89.95% | 20.32% | -13.90% |
Enterprise Value | 1,360 | 1,568 | 1,837 | 3,497 | 2,194 | 1,989 |
Last Close Price | 15.60 | 18.75 | 24.00 | 48.11 | 28.23 | 23.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 123.88 | - | 61.60 |
PS Ratio | 1.03 | 1.24 | 1.49 | 2.88 | 1.65 | 1.44 |
PB Ratio | 0.79 | 0.95 | 1.17 | 2.25 | 1.72 | 1.42 |
P/TBV Ratio | 0.92 | 1.11 | 1.37 | 2.58 | 2.09 | 1.71 |
P/FCF Ratio | 114.70 | 137.86 | 19.18 | - | 25.16 | 27.23 |
P/OCF Ratio | 15.75 | 18.93 | 11.93 | - | 20.00 | 15.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.61 | 1.86 | 2.05 | 3.72 | 2.53 | 2.41 |
EV/EBITDA Ratio | 43.33 | 91.06 | 448.02 | 30.92 | 32.01 | 19.10 |
EV/EBIT Ratio | - | - | - | 65.59 | 368.98 | 49.61 |
EV/FCF Ratio | 178.91 | 206.39 | 26.38 | - | 38.71 | 45.73 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.66 | 0.66 | 0.64 | 0.66 | 1.07 | 1.06 |
Debt / EBITDA Ratio | 23.42 | 23.42 | 38.13 | 6.21 | 11.18 | 7.74 |
Debt / FCF Ratio | 96.72 | 96.72 | 10.44 | - | 15.65 | 20.28 |
Net Debt / Equity Ratio | 0.34 | 0.34 | 0.32 | 0.34 | 0.78 | 0.80 |
Net Debt / EBITDA Ratio | 21.57 | 21.57 | 89.14 | 3.56 | 9.42 | 6.42 |
Net Debt / FCF Ratio | 48.90 | 48.90 | 5.25 | -6.66 | 11.39 | 15.36 |
Asset Turnover | 0.40 | 0.40 | 0.41 | 0.45 | 0.45 | 0.43 |
Inventory Turnover | 2.10 | 2.10 | 2.09 | 2.06 | 2.22 | 1.95 |
Quick Ratio | 1.02 | 1.02 | 1.15 | 1.33 | 0.89 | 0.92 |
Current Ratio | 1.57 | 1.57 | 1.75 | 2.01 | 1.39 | 1.49 |
Return on Equity (ROE) | -3.13% | -3.13% | -4.62% | 3.03% | -0.85% | 2.40% |
Return on Assets (ROA) | -1.31% | -1.31% | -1.64% | 1.59% | 0.19% | 1.31% |
Return on Invested Capital (ROIC) | -2.95% | -2.93% | -3.64% | 2.76% | 0.40% | 2.17% |
Return on Capital Employed (ROCE) | -2.90% | -2.90% | -3.50% | 3.10% | 0.40% | 2.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -3.92% | -3.26% | -4.28% | 0.81% | -0.88% | 1.62% |
FCF Yield | 0.87% | 0.73% | 5.21% | -2.23% | 3.98% | 3.67% |
Dividend Yield | - | - | - | 0.83% | - | - |
Buyback Yield / Dilution | -0.30% | -0.30% | -8.00% | -7.11% | 0.66% | -0.88% |
Total Shareholder Return | -0.30% | -0.30% | -8.00% | -6.28% | 0.66% | -0.88% |